白斑症市場:KOL的洞察

本報告提供全球白斑症市場相關調查，市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

白斑症的治療流程

調查目的

Janus激酶(JAK)抑制劑

• 已上市治療方法
  • Opzelura (ruxolitinib; Incyte Corporation)
• 開發平台療法
  • Ritlecitinib (PF 6651600; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
  • Povorcitinib (INCB054707; Incyte Corporation)

PDE4抑制劑

• 開發平台療法
  • Crisaborole (AN-2728)及PF 07038124(Pfizer)

單株抗體

• 開發平台療法
  • Ordesekimab(AMG 714，Amgen)
  • EB06(NI-0801，Edesa Biotech/Light Chain Biosciences)

MC1R促效劑

• 開發平台療法
  • Scenesse(Afamelanotide，Clinuvel Pharmaceuticals)

白斑症的今後治療趨勢

• 重要洞察的彙整

附錄

While KOLs say Incyte Corporation's Opzelura is a significant advance over existing treatments for vitiligo, what factors do they identify that could initially limit uptake? Why are dermatologists sceptical about the prospects for Pfizer's pipeline JAK inhibitor ritlecitinib in vitiligo? What advantages do KOLs see for IL-15 inhibitors such as Amgen's ordesekimab? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary

Treatment algorithm for vitiligo

Research objectives

Janus kinase (JAK) inhibitors

• Marketed therapies
  • Opzelura (ruxolitinib; Incyte Corporation)
• Pipeline therapies
  • Ritlecitinib (PF 6651600; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
  • Povorcitinib (INCB054707; Incyte Corporation)

PDE4 Inhibitors

• Pipeline therapies
  • Crisaborole (AN-2728) and PF 07038124 (Pfizer)

Monoclonal antibodies

• Pipeline therapies
  • Ordesekimab (AMG 714; Amgen)
  • EB06 (NI-0801; Edesa Biotech/Light Chain Biosciences)

MC1R agonist

• Pipeline therapies
  • Scenesse (Afamelanotide; Clinuvel Pharmaceuticals)

Future treatment trends in vitiligo

• Key insights summary

Appendix

• KOL details
  • KOLs from the US
  • KOLs from Europe